What the infectious disease physician needs to know about pegylated interferon and ribavirin.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23429551.
- Also identified by DOI 10.1093/cid/cit074 and PMC identifier 3641865.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management. Finally, the continued role of peginterferon and ribavirin in future therapies will be discussed.
Medical subject headings
- Antiviral Agents
- Hepatitis C, Chronic
- Interferons
- Polyethylene Glycols
- Ribavirin